Prof. Ashraf Tabll
Applied Medical Biotechnology, Egypt Center for Research and Regenerative Medicine, Cairo, Al Qāhirah, Egypt
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
29Years (1998-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications1 July 2007 in Journal of Immunoassay and Immunochemistry
Journal Article
ERElrashdy M. Redwan
Elrashdy M. RedwanAshraf TabllHepatitis C virus (HCV) is a serious worldwide health risk and, to date, no effective treatments to prevent progression to chronic infection have been discovered. To combat the disease, Egyptian patients often use traditional medicines, for instance, camel milk, which contains lactoferrin. Currently, lactoferrin is one of the primary biopharmaceutical drug candidates against HCV infection. Camel lactoferrin (cLf) purification and biochemical and immunological characterization have shown its similarity to human and bovine lactoferrin, and crossreacts with the anti‐human lactoferrin antibody. Incubation of human leukocytes with cLf then infected with HCV did not prevent the HCV entry into the cells, while the direct interaction between the HCV and cLf leads to a complete virus entry inhibition after seven days incubation. Our results suggest that the cLf may be one of the camel milk components having antiviral activity. In conclusion, we have demonstrated the potential for cLf to inhibit HCV entry into human leukocytes with more efficiency than human or bovine lactoferrin.
13 April 2011 in Journal of Gastroenterology and Hepatology
Journal Article
MAMostafa El Awady
Mostafa El AwadyMAMohamed Mohamed Anany
Mohamed Mohamed AnanyGEGamal Esmat
Gamal EsmatNZNaglaa Zayed
Naglaa Zayed
Ashraf TabllNDNoha G Bader El Din
Noha G Bader El Din +7
Journal Article
AEAshraf Elbahrawy
Ashraf ElbahrawyHAHassan Atalla
Hassan AtallaMAMohamed Alboraie
Mohamed AlboraieِAِAhmed Alwassief
ِAhmed AlwassiefAMAli Madian
Ali Madian
Hussein Hassan Aly +2
Vaccination has been confirmed to be the safest and, sometimes, the only tool of defense against threats from infectious diseases. The successful history of vaccination is evident in the control of serious viral infections, such as smallpox and polio. Viruses that infect human livers are known as hepatitis viruses and are classified into five major types from A to E, alphabetically. Although infection with hepatitis A virus (HAV) is known to be self-resolving after rest and symptomatic treatment, there were 7134 deaths from HAV worldwide in 2016. In 2019, hepatitis B virus (HBV) and hepatitis C virus (HCV) resulted in an estimated 820,000 and 290,000 deaths, respectively. Hepatitis delta virus (HDV) is a satellite virus that depends on HBV for producing its infectious particles in order to spread. The combination of HDV and HBV infection is considered the most severe form of chronic viral hepatitis. Hepatitis E virus (HEV) is another orally transmitted virus, common in low- and middle-income countries. In 2015, it caused 44,000 deaths worldwide. Safe and effective vaccines are already available to prevent hepatitis A and B. Here, we review the recent advances in protective vaccines against the five major hepatitis viruses.
Journal Article
MOMona Ali Omar
Mona Ali OmarMOMohamed Omran
Mohamed OmranKFKhaled Farid
Khaled FaridAshraf TabllYSYasser Shahein
Yasser ShaheinMSMartina Smolic
Martina Smolic +5
The incidence of hepatocellular carcinoma (HCC) and HCC-related deaths has increased over the last few decades. There are several risk factors of HCC such as viral hepatitis (B, C), cirrhosis, tobacco and alcohol use, aflatoxin-contaminated food, pesticides, diabetes, obesity, nonalcoholic fatty liver disease (NAFLD), and metabolic and genetic diseases. Diagnosis of HCC is based on different methods such as imaging ultrasonography (US), multiphasic enhanced computed tomography (CT), magnetic resonance imaging (MRI), and several diagnostic biomarkers. In this review, we examine the epidemiology of HCC worldwide and in Egypt as well as risk factors associated with the development of HCC and, finally, provide the updated diagnostic biomarkers for the diagnosis of HCC, particularly in the early stages of HCC. Several biomarkers are considered to diagnose HCC, including downregulated or upregulated protein markers secreted during HCC development, circulating nucleic acids or cells, metabolites, and the promising, recently identified biomarkers based on quantitative proteomics through the isobaric tags for relative and absolute quantitation (iTRAQ). In addition, a diagnostic model used to improve the sensitivity of combined biomarkers for the diagnosis of early HCC is discussed.
1 January 2003 in Cancer Detection Prevention
Journal Article
AAAbdelfattah M. Attallah
Abdelfattah M. AttallahMAMohamed Mohamed Abdel-Aziz
Mohamed Mohamed Abdel-AzizAEAmina Mohamed El-Sayed
Amina Mohamed El-Sayed
Ashraf Tabll30 April 2012 in Hepatitis Monthly
Journal Article
MAMostafa El Awady
Mostafa El AwadyLMLotiaf Mostafa
Lotiaf Mostafa
Ashraf TabllTATawfeek H. Abdelhafez
Tawfeek H. AbdelhafezNDNoha G Bader El Din
Noha G Bader El DinAAAshraf O. Abdel Aziz
Ashraf O. Abdel Aziz
+6
Association of IL28B SNP With Progression of Egyptian HCV Genotype 4 Patients to End Stage Liver Disease - Hepatitis Monthly - 2012 - Kowsar
About Me
Professor Dr. Ashraf Abdou Saleh Tabll is a leading Egyptian scientist in medical biotechnology and immunology, currently serving as Professor of Medical Biotechnology at the Egypt Center for Research and Regenerative Medicine (ECRRM) (formerly NAMRU-3), Egypt. He is also a Professor of Medical Biotechnology at the Microbial Biotechnology Department, Biotechnology Research Institute, National Research Centre (NRC).
Prof. Tabll earned his Ph.D. in Biochemistry (2001) from Cairo University, where his research focused on cellular and molecular biomarkers in liver diseases. He previously obtained an M.Sc. in Chemistry (Menoufia University, 1997), an M.Sc. in Medical Microbiology (Military Medical Academy, 1993), and a B.Sc. in Science from Mansoura University (1990).
With over 108 international publications in reputable journals, Prof. Tabll’s research spans immunodiagnostics, immunotherapy, monoclonal and IgY antibody development, virology, and vaccine design as well as Cancer Biology. He has played a pioneering role in establishing cell line systems for the production of monoclonal antibodies and chicken egg yolk (IgY) antibodies for therapeutic and preventive applications against hepatitis viruses, MERS-CoV, and COVID-19. His work led to several Egyptian and international patents, including a U.S. patent (No. 11,319,382, 2022) for IgY antibodies against MERS-CoV.
Prof. Tabll has been a principal investigator and collaborator on numerous national and international research proj